INTRODUCTION
Age-incidence curves of most common epithelial cancers show rapidly increasing rates after the 4 th -5 th decades of life. Classic mathematical models of tumor development developed by Armitage and Doll (Armitage and Doll, 1954; Hornsby et al., 2007) suggested that 5-8 rate-limiting events are required to generate such incidence patterns. Since these studies were performed in the 1950s, we have learnt much about the biological and genetic basis of cancer. In particular, evolution toward cancer often occurs on a phenotypic spectrum of increasingly disordered premalignant stages, as ''hallmark'' cellular processes are cumulatively co-opted or ablated in the cancer cells (Hanahan and Weinberg, 2011) . Somatic mutation is the fundamental mechanism by which cancer cells suborn these pathways (Stratton et al., 2009) , notwithstanding the contributions of epigenetic changes, cues from the local microenvironment and germline genetic variation.
Whole-cancer genomes sequenced to date carry thousands to tens of thousands of somatic mutations (Chapman et al., 2011; Ding et al., 2010; Ley et al., 2010; Pleasance et al., 2010a Pleasance et al., , 2010b Puente et al., 2011; Shah et al., 2009 ), the vast majority of which probably have no biological relevance. The accumulation of mutations in cancerous and precancerous cells over time is increasingly recognized as a complex, dynamic process. Carcinogenic exposures and DNA repair defects can lead to sustained elevations in mutation rate; telomere attrition and chromothripsis can drive massive genomic rearrangement in catastrophic bursts Campbell et al., 2010; O'Hagan et al., 2002; Stephens et al., 2011) .
In the classic view of cancer development, those somatic mutations conferring a selective advantage on the cell drive successive waves of clonal expansion, with the fittest clone coming to dominate the cellular compartment. Increasingly, however, cancers are recognized to be mixtures of competing subclones, based on analyses of cancers sampled within a patient at different times (Ding et al., 2012; Shah et al., 2009) , from different sites (Campbell et al., 2010; Ding et al., 2010; Yachida et al., 2010) , at hypermutable genomic loci (Campbell et al., 2008) , or through single-cell isolation (Anderson et al., 2011; Navin et al., 2011; Notta et al., 2011) . Although these studies imply the existence of genetic heterogeneity within a tumor, fundamental questions remain about the dynamics of Darwinian evolution in cancer, the biological relevance of subclonal genetic variation and the relationship between mutational processes and clonal expansion.
Here, we use newly developed bioinformatic algorithms to reconstruct the genomic history of 21 breast cancers. Borrowing the concept of a ''most-recent common ancestor'' from population genetics, we can divide somatic mutations into those acquired before the last complete selective sweep (and thus shared by all cancer cells within the sample) and those subclonal variants that occurred after the emergence of the common ancestor. We study the early genomic evolution of the eventual cancer clone, quantify the extent and dynamics of subclonal variation within the cancer sample sequenced and explore changes in mutation signatures over time. These findings have important implications for our understanding of how breast cancers develop over the decades between breast organogenesis and diagnosis in the adult.
RESULTS

Inference of Cancer Genome Evolution
We sequenced 20 primary breast cancer samples to an average 30-40 coverage across each base in the genome. The sample series includes four cases each of estrogen-receptor (ER)-positive, HER2-positive, and BRCA2-positive breast cancer; three cases of triple negative; and five cases of BRCA1-positive breast cancer. In addition, we sequenced to 188-fold depth one other ER-positive tumor with a distinctive mutator phenotype, consisting of C>A, C>G and C>T mutations specifically in a TpC context. As described in the companion paper to this , this issue of Cell), we identified a highconfidence, validated set of base substitutions, insertions, and deletions (indels); genomic rearrangements; and copy number changes in the 21 cancers.
To develop the reasoning that underpins this paper, we start with the tumor sequenced to 188-fold depth, PD4120a. At the chromosomal scale, the cancer genome is hypodiploid, with relatively few copy number changes ( Figure 1A ). To exploit the considerable sequencing depth available for this tumor, we modified the parameters of our somatic substitution algorithm in order to identify subclonal mutations; those found in only a fraction of tumor cells. In total, we identified 70,690 somatic substitutions genome-wide, including many in which fewer than 5% of the reads across the base reported the variant allele. That these are bona fide mutations is evidenced by the dominance of the C>* mutations in a TpC context at all levels of subclonality (Figures S1A and S1B, available online) and a high rate of verification in a subset by targeted PCR and pyrosequencing.
The mutations fall into well-circumscribed clusters when displayed by the fraction of reads reporting the variant ( Figure 1B and Figure S1C ). The major cluster of points occurs at a read depth around 210, with about 35% of reads reporting each variant. Because an estimated 70% of cells in the sample derive from the cancer clone, this cluster represents those point mutations found in all tumor cells on one copy of a diploid chromosome. By comparison, mutations from regions of copy number 1 show a lower overall read depth (because the copy number is lower) but higher variant allele fraction (because there are no reads from the deleted chromosome).
The genome has one triploid chromosomal region, 1q, which is most likely to have arisen as a single gain of one whole chromosome arm, although we cannot formally exclude duplication of both alleles with subsequent loss of one. Mutations occurring on the relevant chromosomal arm before duplication would be present on two of three copies (with an expected variant allele fraction of $55%), whereas mutations occurring after the duplication would be present on only one copy. In fact, we find only seven mutations on 1q predicted to have occurred before the chromosome arm was duplicated, not one of which has the signature of C>* mutations in a TpC context ( Figure S1C ). In contrast, 1,250 mutations are found on 1q at single copy number, of which 1,130 have this mutation signature, with the spectrum of early (ploidy 2) and late (ploidy 1) mutations being significantly different (p < 0.0001, chi-square test). Trisomy 1q is one of the commonest copy number alterations seen in breast cancer (Beroukhim et al., 2010; Bignell et al., 2010) . Our data indicate that, relative to point mutations, this driver cytogenetic change occurred very early during the evolution of this particular tumor. Furthermore, albeit with small numbers of informative early mutations, the mutator phenotype was not evident before the occurrence of trisomy 1q.
Modeling Clonal and Subclonal Mutation Clusters
Many of the mutations we identify are present at a lower proportion of reads than we would expect for the ploidy and level of normal cell contamination in the sample ( Figure 1B ). These are subclonal mutations, found in only a fraction of the tumor cells. A particularly striking feature of these mutations is that they seemingly fall into distinct clusters.
These data imply that the population of tumor cells within this breast cancer sample contains several discrete subclones, each of which represents a certain fraction of tumor cells and contains a certain number of substitutions (namely the size of the cluster). To enable formal development of this concept, we explicitly modeled the observed patterns of clonal and subclonal mutations with a hierarchical Bayesian Dirichlet process (Dunson, 2010) . Using this flexible approach, we model the mutations as deriving from an unknown number of subclones, each of which is present at an unknown fraction of tumor cells and contributes an unknown proportion of all somatic mutations, with all the unknown parameters to be jointly estimated in the model (Extended Experimental Procedures).
The model performs well on simulated data sets, recapturing the ''true'' underlying distribution of subclones accurately, across variable numbers and sizes of subclonal populations ( Figures S2A-S2C) . We therefore applied this model to mutations found in PD4120a ( Figure 1C and Figure S2D ). This clearly shows four distinct clusters of mutations, one set found in all tumor cells (which we call cluster D henceforth) and three clusters of subclonal mutations, centered on variant allele fractions of 5% (cluster A), 11% (cluster B), and 19% (cluster C). From the model, we can generate estimates of the number of mutations found in each of these clusters together with 95% posterior confidence intervals for the estimates ( Figure 1D) .
The model predicts that some 26,762 mutations (95% posterior interval, 22,378-31,160) are found in all tumor cells in PD4120a. The implication is that during the evolution of this cancer, there was some ancestral cell that carried this complement of somatic mutations. Borrowing the term from population genetics, we term this cell the ''most-recent common ancestor'' of the tumor, and its emergence demarcates the split between mutations that are fully clonal and those that are subclonal. Among the mutations acquired before the emergence of the most-recent common ancestor are several in cancer genes, including TP53, PIK3CA, GATA3, MLL3, SMAD4, and NCOR1. In addition, the trisomy 1q described above had occurred, as well as an unbalanced t(1;22) translocation and a cluster of chromothripsis rearrangements involving chromosomes 2, 4, 18, and 21 ( Figure S2E ).
Subclonal Loss of Multiple Chromosomes in PD4120a
The copy number profile for chromosome 13 in PD4120a reveals that it is deleted in some, but not all, tumor cells ( Figure 1A ). The logR values, which measure total copy number, show decreased intensity compared to diploid chromosomes but higher than monosomic chromosomes. The allele fraction plot, which reports the relative proportions of the two alleles for heterozygous SNPs, shows similarly intermediate levels for chromosome 13. From these variables, we estimate that 68% of tumor cells have one copy of chromosome 13 deleted (95% confidence interval, 67%-69%). The same pattern is seen for 22q, indicating (A) Battenberg plots of allele fractions for phased parental haplotypes for four chromosomes. Germline SNPs are phased by imputation, with observed allele fraction for one phased chromosomal copy plotted in blue and the other in red.
(B) Phasing of mutations (stars) with adjacent germline heterozygous SNPs (vertical lines) allows determination of whether a mutation is on the retained or subclonally deleted parental copy of a chromosome.
(C) Distribution of somatically acquired base substitutions on chromosome 13 according to the total number of reads across that base (x axis) and the fraction of those reads reporting the variant (y axis). Points are colored according to whether the mutation derives from the retained copy of chromosome 13 (green points), the subclonally deleted copy of chromosome 13 (brown points) or whether it could not be phased with a nearby heterozygous SNP (black points).
that the t(1;22) derivative chromosome has been deleted in a similar fraction of cells. Allele frequency plots for chromosome 7 also appear slightly more widely distributed around 0.5 than other diploid chromosomes, associated with a concomitant small decrease in logR levels overall for this chromosome (Figure 1A) , suggesting that the chromosome is lost in a minor fraction of tumor cells. With data from the 1000 Genomes Project (1000 Genomes Project Consortium, 2010 , it is now possible to impute linkage of many germline SNPs into parent-specific haplotype blocks. We hypothesized that analysis of allele ratios by haplotype rather than individual SNP would draw out subtle deviations from the expected fraction of 0.5 with substantially improved statistical power and developed a bioinformatics method to assess this (the ''Battenberg'' algorithm; Extended Experimental Procedures). Applying it to chromosome 3 demonstrates no evidence for subclonal variation in copy number, as parentspecific allelic fractions in red and blue are superimposed at 0.5, as expected ( Figure 2A ). In contrast, for chromosome 7, red and blue patches marking parent-specific haplotypes show clear separation, indicative of subclonal deletion of the chromosome in a small fraction of tumor cells. Remarkably, when we apply this analysis genome-wide, we find that 14 chromosomes overall show statistically significant evidence for subclonal copy number variation ( Figure 2A and Figure S3A ). For these other regions, which include chromosomes 6, 8, 9, 11, 12, 14, and 15, the extent of separation is similar and less than that observed for chromosome 7.
Chromosome 2 shows an interesting pattern of changes. The logR values for ''diploid'' regions of chromosome 2, measuring overall copy number, are clearly lower than those for chromosome 5 (average logR, 0.020 versus 0.161; p < 10
À308
) but virtually the same as for chromosome 7 (average logR, 0.020 versus 0.017; Figure S3B ), implying that chromosome 2 is subclonally deleted in a similar proportion of cells to chromosome 7. However, the haplotype-specific phasing analysis described above confirms that the allele fraction at ''diploid'' regions of the chromosome is exactly balanced at 0.5 ( Figures S3A and  S3B ). The implication therefore is that chromosome 2 is subclonally deleted in PD4120a, but both parental copies have been lost in an exactly balanced proportion of cells.
In summary, these analyses indicate subclonal deletion of chromosome 13 in $68% of tumor cells. There is also evidence for loss of chromosome 7 in a smaller fraction of cells, and for losses of other chromosomes, including 6, 8, 9, 11, 12, 14, 15, 18 , and 21 in an even smaller proportion. Finally, there is convincing evidence that both parental copies of chromosome 2 have been lost in exactly equal proportions.
Integrating Subclonal Point Mutations and Copy Number Changes As discussed above, there is a cluster of $15,600 subclonal point mutations found at a variant allele fraction of $19% (cluster C). Because this variant allele fraction is more than half that of the fully clonal mutations, each of these mutations is present in more than 50% of tumor cells. Consider any two of these mutations. By the so-called ''pigeonhole principle,'' there must be at least one tumor cell that contains both mutations, because there is no way to apportion two lots of > 50% to completely separate subsets. Therefore, the two variants must be collinear on the phylogenetic tree. If this reasoning applies for any two such mutations at > 50%, then it applies to all such mutations en bloc. Furthermore, if one such mutation is found in a strictly greater fraction of cancer cells than another such mutation, then it must have occurred earlier than the other. Applying these deductions to PD4120a, it follows that the mutations found in cluster C are all on the same branch of the phylogenetic tree, together with the subclonal deletion of chromosome 13. Furthermore, because the deletion is found in a larger proportion of cells, it must have occurred earlier during the cancer's evolution than cluster C mutations.
We can directly test the veracity of this reasoning. Because we reason that the deletion of 13 occurred before subclonal mutations in cluster C, we predict that those subclonal mutations could only involve the retained copy of chromosome 13. Many somatic mutations will be sufficiently close to heterozygous germline SNPs that individual sequencing read pairs will span both, thus allowing the mutation to be ''phased'' with the SNP ( Figure 2B ). Of the 2,171 mutations on chromosome 13, we were able to phase 756 (35%) with a nearby heterozygous SNP, thus unambiguously determining whether the mutation occurred on the parental copy of chromosome 13 that was subclonally deleted or on the retained copy ( Figure 2C ). We find a cluster of mutations on the retained copy of chromosome 13 at a variant allele frequency of $48% (green points, Figure 2C)-this represents fully clonal mutations (cluster D). We also see a cluster of mutations from the deleted copy of chromosome 13 at $15% (brown points), denoting ancestral mutations subsequently deleted in 68% of tumor cells. A third distinct cluster of mutations is evident at $25% of reads, the equivalent of cluster C. All of these, as predicted, are phased with the retained copy of chromosome 13. This approach is also informative for the other subclonally deleted chromosomes. For mutations on the retained copy of chromosomes 6, 7, 8, and 11, we find clusters A-D as for nonsubclonal diploid chromosomes ( Figure 3A and data not shown). For mutations on the parental copies of chromosomes 6 and 7 that are subclonally deleted, cluster B is completely lost, whereas the others remain unchanged. This demonstrates that virtually all mutations in cluster B are on a separate phylogenetic branch from mutations in cluster C. Furthermore, the subclonal deletion of chromosome 6 and 7 must be collinear with the mutations in cluster B. The same patterns and reasoning apply to chromosome 8, 11, 12, 14, 15, 18 and 21 . For chromosome 2, we find that cluster B is abolished on both parental copies of the chromosome. This confirms the observation from the logR values that both copies of chromosome 2 are subclonally deleted ( Figure S2B ) and moreover places these deletions on the same branch as the mutations in cluster B.
In summary, these data indicate that the subclonal deletion of chromosome 13 and the mutations in cluster C are on the same branch of the phylogenetic tree, with del13 occurring first. On a separate branch of the tree from this dominant subclone, we find all the mutations in cluster B, together with subsequent subclonal deletion of chromosomes 2, 6, 7, 8, 9, 11, 12, 14, 15, 18 , and 21.
Phasing Pairs of Subclonal Somatic Mutations
We can also attempt to phase any two somatic mutations that are sufficiently close together to be spanned by single read pairs. We recognize two informative scenarios. The two mutations could arise in completely independent subclones, in which case reads could report either variant alone but never the two together ( Figure S4A ). Alternatively, one mutation could occur as subclonal evolution in a cell that already contains the other mutation, in which case we would see reads that report the earlier variant only as well as reads that report both variants together ( Figure S4B ). It is only valid to identify mutually exclusive mutation pairs in chromosomes that are haploid in the tumor, and we do indeed find 17 such pairs ( Figure 3B and Figure S4C ). Genome-wide, we also identify 76 examples of sub-subclonal evolution occurring on the same allele as a pre-existent subclonal mutation ( Figure 3C , and Figure S4D ). Strikingly, there are no examples of sub-subclonal evolution at 9%-12% variant allele fraction (cluster B) occurring in conjunction with a mutation at > 16% allele fraction (cluster C), confirming that mutations in cluster B fall on a separate phylogenetic branch from those in cluster C.
These data also indicate that cluster A, the set of mutations at a variant allele fraction $5%, is likely to contain several discrete subclones. Some of these variants are clearly subclonal to cluster C and others subclonal to cluster B, as shown in Figure 3C . However, most are not derived from cluster B, because the peak for cluster A is largely unchanged for the parental copy of chromosome 7 that is subclonally deleted ( Figure 3A ). Mutations in cluster A frequently fell in mutually exclusive subclones ( Figure 3B ) and hence on different branches of the phylogenetic tree. It is therefore probable that some or even most of the cluster A mutations represent a third branch from the most-recent common ancestor. In support of this is a pair of cluster A mutations, both of which phase with the subclonally deleted copy of chromosome 13, and hence cannot be placed on the del13 branch, but are mutually exclusive with one another ( Figure S4E) .
A Phylogenetic Tree for PD4120a
With these observations, we can integrate the subclonal chromosome-scale losses with the subclonal point mutations to reconstruct how the tumor has evolved ( Figure 3D ). In one branch of the phylogenetic tree, there has been loss of chromosome 13 and subsequent acquisition of cluster C mutations. The other branch of the phylogenetic tree contains the cluster B mutations and sub-subclonal losses of multiple chromosomes, including both parental copies of chromosome 2. Because homozygous deletion of chromosome 2 in a diploid cell is frankly implausible, the most likely model is that a sub-subclone of the cluster B subclone has become tetraploid, presumably through an endoreduplication event. It has subsequently lost one of the four copies of chromosomes 6, 8, 9, 11, 12, 14, 15, 18, and 21 . In addition, both copies of the same parental chromosome 7 have been lost, and one of each parental copy of chromosome 2 has been lost. From this model, we estimate that the subclone with mutations in cluster C represent 65% of tumor cells, cluster B represents 18% of tumor cells, and the tetraploid subclone represents 14% of tumor cells. Mutations in cluster A account for 14% of tumor cells. If many of these do fall on a third branch of the phylogenetic tree, the three branches would neatly account for all descendants of the most-recent common ancestor because the 14% of tumor cells in cluster A, the 68% with deletion 13, and the 18% of tumor cells in cluster B together add up to 100%. This phylogenetic tree explains all data observed for PD4120a.
Timing Chromosomal Evolution in 20 Breast Cancer Genomes Chromosomal instability, the gains and losses of whole chromosomes or chromosome arms, is a well-recognized feature of breast cancer cells probably caused by missegregation of chromosomes during cell division (Burrell et al., 2010) . As outlined above, for genomic regions that have increased in copy number, we can estimate the timing of the duplication event by comparing the proportion of mutations at ploidy 1 and ploidy 2 . Among the 20 breast genomes sequenced to 30-to 40-fold depth, 16 had informative genomes for timing chromosomal gains (Figure 4) . Broadly, the data suggest that the onset of large-scale chromosomal gains did not begin across these genomes until after at least 15%-20% of point mutation time had elapsed but thereafter continued steadily in many tumors. The implication is that chromosomal instability is not usually the earliest source of mutation in breast cancer evolution, but is a common and on-going process in later stages.
A related phenomenon is that of whole-genome duplication, caused by a single event of cytokinesis failure, endoreduplication, or fusion of two diploid cells. Ten of the tumors studied here show evidence for such an event, inferred from the homogeneity of the distribution of early and late mutations across the genome (Figure 4 and Figure S5A ). In general, such endoreduplication was a late event in this series, occurring after more than 50% of point mutation time had elapsed and often following many preceding single chromosome losses and gains.
Five informative tumors had genomic amplifications of known cancer genes, three involving ERBB2 and one each involving MYC and CCND1. In four of the five cases, no mutations were present on all copies of the amplified segment, even allowing for the one patient where both parental copies of the locus contributed to the amplification (Figures S5B and S5C ). Therefore, the first rearrangement driving the genomic amplification presumably occurred early in the evolution of these cancers. Interestingly, however, all amplifications showed multiple mutations at several discrete stages of ploidy intermediate between all copies and only one copy of the amplified region ( Figures  S5B and S5C ). These mutations must have accumulated after the amplification had begun, because they do not involve all copies, but before the amplification was complete, because their ploidy is more than 1. Coupled with the fact that such mutations were observed at several discrete levels of ploidy, these data suggest that the genomic rearrangements driving the amplifications in these patients were acquired over a relatively protracted period of molecular time. This pattern is different to mechanisms of genomic amplification such as breakage-fusion-bridge or double minute chromosomes, where amplification can occur rapidly and even exponentially over a few cell cycles Campbell et al., 2010; Stephens et al., 2011) .
Changing Spectrum of Mutations over Time
In addition to timing when chromosomal gains occur, we can compare the spectrum of point mutations acquired early, before the copy number gain (ploidy 2), and late, after the gain (ploidy 1) (Pleasance et al., 2010a) . Fourteen of the genomes had sufficient numbers of early and late mutations to enable statistical comparison of the mutation spectrum over time ( Figure 5A ). Of these, 11 had statistically significant differences in spectrum between mutations acquired early and late, with many patients showing a strikingly different profile.
The most consistent pattern is that C>T transitions constitute a higher proportion of early mutations than of late mutations, with 10/14 genomes showing a statistically significant decrease in C>T ratios after chromosome gains. C>T transitions are frequently caused by spontaneous deamination of methylated cytosine to thymine. However, we find that, in general, the decreased proportion of C>T mutations over time applies equally to other contexts as to those at CpG dinucleotides ( Figure S6 ).
In the companion paper to this one (Nik-Zainal et al., 2012), we show that many breast cancer genomes have distinctive mutation processes, from which a nonnegative matrix factorization algorithm identified five separate signatures. By classifying whether mutations were early clonal (ploidy > 1), late clonal (ploidy = 1) or subclonal (ploidy < 1) in regions of copy number gains, we could assess the relative contributions of these five processes at different times during a cancer's evolution. In 8 patients, sufficient numbers of mutations were present in such regions to generate a stable solution ( Figure 5B ). This confirms that C>T mutations at CpG dinucleotides, termed ''signature A,'' contributes a large proportion of the early mutations in these cancers, and relatively few late in the evolution of the tumors. In contrast, ''signature E,'' denoting C>G mutations at TpCpA, TpCpC and TpCpT trinucleotides, is a late onset mutational signature, contributing a large fraction of subclonal mutations in many patients. A similar pattern is seen for ''signature B '' comprising C>G Duplication: 1, 2, 3p, 4, 5q, 6, 7, 8p, 9, 10q, 11q, 13, 14, 15, 17, 20p, 21, 22 Trisomy: 2, 3, 7, 9q, 12q, 16, 18, 20 Duplication 3, 4p, 5, 8p, 10, 11q, 13, 14q, 15, 17p Duplication 1q, 2, 5, 6, 7p, 9, 11, 12, 13, 14, 15q, 17p, 18, 20, 21, 22 PD4107a Duplication: 3p, 4p, 10, 11q, 14, 15, 18, 20, 21, 22 UPD17q (BRCA1) Duplication: 3, 5, 6, 10, 11, 15, 20 +8q 95% confidence intervals were also significantly over-represented among late mutations than early events (odds ratio, 1.9; p < 0.0001). Taken together, these data indicate that the mutational forces fashioning the breast cancer genome vary over time. C>T transitions, both at CpG dinucleotides and in other sequence contexts, play a significant role in the early acquisition of mutations, accounting for up to 40% of mutations acquired before chromosomal gains. To some extent, the profile of base changes seen among many of the early breast cancer variants is a default mutation spectrum, closely mirroring that seen in tumor types such as blood, pancreatic, and brain cancers Jones et al., 2008; Papaemmanuil et al., 2011; Puente et al., 2011) and indeed in germline nucleotide substitutions (Hwang and Green, 2004) . The lower proportional contribution of C>T transitions among late mutations is most likely caused by an increase in the rate of other mutation types because tumor-specific signatures account for much of the variation between early and late mutations. Intriguingly, we find that there are several mutation signatures at play in many of these patients, contributing varying proportions of mutations and with onset at different times during cancer evolution. The implication therefore is that in most breast cancers, the mutation rate increases in more advanced stages of tumor development, driven by distinctive, cancer-specific mutational processes. These processes continue past the emergence of the mostrecent common ancestor, driving subclonal diversification within the tumor.
Timing Kataegis, Localized Clusters of Mutations
In the companion paper to this one (Nik-Zainal et al., 2012), we describe localized clusters of C>T and C>G mutations occurring in a TpC context closely associated with genomic rearrangements, which we termed kataegis. The presumption here is that an individual cluster of mutations occurs in a single event because of the close association with rearrangements and the fact that there is a strong strand bias within a cluster. Although the mutations within each cluster might occur simultaneously, however, the relative timing of different clusters of kataegis is not clear.
In PD4103a, there are many clusters of kataegis mutations genome-wide. Interestingly, within the amplicon involving regions of chromosomes 10, 11, and 12, we find that these clusters occur at several different levels of ploidy ( Figure 5C ). For example, on chromosome 12, there are several such events found at variant allele fraction of 0.8 or higher in association with rearrangements that demarcate large copy number changes. These must have occurred early in the genesis of the amplicon and then themselves been amplified by subsequent rearrangements. Interestingly, there is also a cluster at an allele fraction of 0.4 and several at allele fractions < 0.1. These must have occurred later in the genesis of the amplicon. In addition, rearrangements in PD4103a outside this amplicon are also associated with kataegis, such as a deletion of TP53 ( Figure 5C ). The implication is that these clusters of mutations have not all occurred in a single event.
The other patient with particularly high numbers of these clusters, PD4107a, shows a somewhat different pattern. Here, the kataegis mutations are found specifically in association with a chromothripsis event on chromosome 6 and are all at the same level of ploidy. Thus, it seems very likely that both the chromothripsis and kataegis mutations did occur in the same catastrophic event. Nonetheless, elsewhere in this patient, there are other rearrangements with adjacent kataegis clusters, again arguing that this process can occur recurrently during the evolution of a breast cancer.
Dominant Subclones Are Always Present in Breast Cancers
In PD4120a, the high sequencing depth enables us to infer the existence of several subclonal expansions. For the 20 genomes sequenced at 30-to 40-fold coverage, there is a measurable probability that a sufficient number of reads will report a subclonal variant to allow our algorithm to call the mutation. We estimated this probability by using a statistical resampling method known as bootstrapping (Extended Experimental Procedures). On average for the 20 genomes, we have an approximately 90% chance of detecting a fully clonal mutation, a 60% chance of detecting a mutation found in 50% of tumor cells, and a 5% chance of detecting a mutation in 25% of tumor cells (Figure S7A ). For 19 of the genomes reported here, 150-300 somatic substitutions were independently verified by PCR and deep pyrosequencing on the 454 platform, giving accurate estimates of the variant allele fraction for these mutations. For four samples in which exome pull-down and sequencing was also performed, the empiric distributions of subclonal mutations called in the original genome and subsequently validated by deep pyrosequencing or exome pull-down are very similar ( Figure S7B) .
We therefore applied the Bayesian Dirichlet process described earlier to the deep sequencing data, adding correction for the sample-specific sensitivity for detecting mutations at different levels of subclonality (Figures 6A and 6B and Figure S7C ). We find subclonal point mutations in all samples studied and indeed the estimated number of these genome-wide is, for most samples studied, more than the number of fully clonal mutations ( Figure 6A ). As for PD4120a, we always find evidence for a dominant subclonal lineage, comprising mutations found in 50%-95% of tumor cells, which the pigeonhole principle dictates must all be on the same branch of the phylogenetic tree. The patterns and distribution of this subclonal variation show diversity across the genomes, with some samples composed of a broad range of subclones at differing fractions of tumor cells (PD4088a, PD3905a, and PD4199a) and others showing fewer, more distinct subclonal expansions (PD4116a, PD4005a, and PD4085a). Overall, however, by the arguments above, all show a single dominant lineage of subclonal and sub-subclonal expansions within the population of cancer cells.
We can also apply the ''Battenberg'' analysis used for PD4120a, in which we phase haplotypes of germline heterozygous SNPs, to investigate subclonal copy number gains and losses in the other 20 genomes ( Figure 6C ). Again, we find considerable diversity in the frequency and patterns of subclonal regional variation. Some samples, such as PD4088a and PD4248a, showed very little subclonal copy number variation, but in other genomes, such as PD3851a, PD4085a, and PD4116a, the vast majority of the genome varies in copy number among different subclones within the cancer. Among these genomes, there is also diversity in the number of distinct subclones evident by this analysis. For example, PD4192a shows strong evidence on the Battenberg analysis for a subclone of 40%-50% of tumor cells with regional differences in copy number from other subclones across 10-12 chromosomes. Interestingly, this is matched by a discrete peak of point mutations in 40%-50% of tumor cells ( Figure S7C ). In contrast, many other genomes, such as PD4086a and PD3890a, show evidence for several distinct levels of subclonality across the genome. For three of these samples, we can apply similar (B) Distribution of clonal and subclonal mutations for three representative cancers. The empiric histogram of mutations is shown in pale blue, with the fitted distribution and 95% posterior intervals as dark green lines. (C) Subclonal copy number variation for the 20 breast cancer genomes, estimated by using the Battenberg algorithm. The height of each bar reflects the estimated copy number, and segments are colored by whether they show no subclonal variation (gray) or the estimated frequency of the minor subclone at the given region (green to yellow to brown). The cancer evolves through acquisition of driver mutations (black stars), which produce clonal expansions. These driver mutations occur only infrequently in long-lived lineages of cells, which passively accumulate many mutations without expansion.
reasoning as used for PD4120a to reconstruct the phylogenetic tree of the cancer ( Figure S8 ). In summary, these data indicate that a considerable proportion of somatic genetic variation in these 20 genomes is found in only a fraction of tumor cells. There is heterogeneity among different cases, but as a general rule, there is always a dominant subclonal lineage separated from the most-recent common ancestor by several hundreds to thousands of mutations.
DISCUSSION
A Model of Breast Cancer Development From the analyses described here, we can begin to understand the dynamics of breast cancer development (Figure 7) . A key landmark in this evolution is the appearance of the most-recent common ancestor-the cell that has the full complement of somatic mutations found in all tumor cells. All extant cancer cells in the sample analyzed can trace a genealogy back to the fertilized egg through this common ancestor, and its emergence demarcates the split in the phylogenetic tree from the shared trunk to the branches of divergent subclones. Our data consistently indicate that the most-recent common ancestor appeared surprisingly early in molecular time, or, expressed another way, much of molecular time is spent driving subclonal diversification and evolution among the nascent cancer cells. This is different to what is observed for acute myeloid leukemia, where the proportion of mutations that are subclonal is relatively small (Ding et al., 2012) .
Before the appearance of the most-recent common ancestor, much oncogenic genetic change has accumulated in the lineage. Many of the tumors studied here have several driver mutations that are found in all tumor cells-all PIK3CA and TP53 mutations, all ERBB2, MYC, and CCND1 amplifications, all somatic loss of the wild-type BRCA1 and BRCA2 alleles among these 21 cancers can be placed unequivocally on the shared trunk of the phylogenetic tree. Chromosomal instability appears in many of the tumors from about 15%-20% of the way through molecular time and has an on-going impact thereafter, even beyond the appearance of the most-recent common ancestor. This results in the clonal acquisition of many recurrent abnormalities, such as gains of 1q and 8q and losses of 17p, and considerable divergence among subclones of the cancer in their large-scale chromosomal composition. Like chromosomal instability, other cancer-specific point mutational processes materialize during the tumor's development, having considerable impact on the number and patterns of late mutations.
Several profound insights into the patterns and dynamics of subclonal evolution, occurring after the appearance of the most-recent common ancestor, can be drawn from these 21 breast cancers. All of the tumors contained a dominant subclonal lineage, accounting for more than 50% of cancer cells in the sample and carrying many hundreds or thousands of point mutations. There is no a priori reason why a cancer should have such a dominant subclone, nor why the phylogenetic branch should carry so many mutations. The one unifying factor for all these tumors is, rather obviously, that they have been diagnosed: in other words, they are sufficiently large to be palpable or seen on a mammogram. In a breast cancer of typical size, 10 cm 3 say, the expansion of a subclone that ultimately constitutes 60% of tumor cells will contribute 6 cm 3 to the tumor bulk, assuming stromal contamination and cell size are proportionate. Such a significant fraction of a tumor's mass is likely to have a substantial impact on whether a lesion is clinically detectable or not.
The implication, therefore, is that expansion of a dominant subclonal lineage is the final rate-limiting step in the development of breast cancer, triggering diagnosis. Two important observations underpin this logic. First, the dominant subclone is separated from the most-recent common ancestor by many hundreds to thousands of point mutations, often more than the set of mutations shared by all cancer cells. Second, there is minimal evidence of significant clonal expansion before the accumulation of all mutations in the dominant subclone. This is particularly clearly demonstrated with the high sequence coverage for PD4120a. The dominant subclone here has some $15,600 mutations found in 65% of tumor cells, with very few subclonal mutations found in more than 65% of cells. The event triggering the expansion of this subclone, presumably a somatic mutation, must therefore be rate limiting in the sense that Armitage and Doll (1954) use, because so many mutations stack up before the subclone begins proliferation.
Thus we glimpse a model of long-lived, but sparse, lineages of cells passively accumulating mutations until provoked into a major quest for tumor dominance. It is only when this subclone has grown sufficiently populous that the tumor mass becomes clinically detectable. For the tumors studied here, the number of mutations acquired after the split from the most-recent common ancestor in the lineage that becomes the dominant subclone is often similar to or more than the number acquired before the split, a striking finding given that several driver mutations are already present in the common ancestor. Our model has an obvious similitude with the concept of cancer stem cells-infrequent, self-renewing, metabolically quiescent cells capable of reconstituting a tumor (Anderson et al., 2011; Notta et al., 2011; Visvader and Lindeman, 2008) .
The cancer genome is like a palimpsest, an ancient parchment that was frequently reused, each time retaining traces of what had previously been written. The interplay of point mutations, chromosomal gains and losses, and clonal expansions, acquired in a given temporal sequence, leave an analogous record of the life history of a cancer inscribed in its genome.
EXPERIMENTAL PROCEDURES
The protocols for sequencing and bioinformatics analysis for identification of somatic substitutions, indels, copy number changes and genomic rearrangements are all described in the companion paper to this one . Estimates of normal cell contamination were derived by using the ASCAT algorithm, based on analysis of the B allele fraction for heterozygous germline SNPs for regions departing from diploidy in the tumor genome (Van Loo et al., 2010) . For PD4120a, this estimate includes a correction for the fact that there is a tetraploid subclone.
For analyzing the subclonal structure of PD4120a and the other breast cancer genomes, we developed several new bioinformatics algorithms. These include methods for (1) phasing mutations with nearby heterozygous germline SNPs; (2) phasing pairs of subclonal mutations in close proximity; (3) identifying large-scale subclonal copy number variation (the Battenberg algorithm); and (4) modeling the clusters of subclonal base substitutions from deep coverage data by using Bayesian Dirichlet processes. These algorithms are described in step-by-step detail in Extended Experimental Procedures.
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